{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T00:06:02Z","timestamp":1794009962312,"version":"4.8.0"},"reference-count":24,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2013,6,1]],"date-time":"2013-06-01T00:00:00Z","timestamp":1370044800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,6,1]],"date-time":"2013-06-01T00:00:00Z","timestamp":1370044800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,9,11]],"date-time":"2023-09-11T00:00:00Z","timestamp":1694390400000},"content-version":"vor","delay-in-days":3754,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,6,1]],"date-time":"2013-06-01T00:00:00Z","timestamp":1370044800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2013,6,1]],"date-time":"2013-06-01T00:00:00Z","timestamp":1370044800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2013,6,1]],"date-time":"2013-06-01T00:00:00Z","timestamp":1370044800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2013,6,1]],"date-time":"2013-06-01T00:00:00Z","timestamp":1370044800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2013,6,1]],"date-time":"2013-06-01T00:00:00Z","timestamp":1370044800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jpain.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pain"],"published-print":{"date-parts":[[2013,6]]},"DOI":"10.1016\/j.jpain.2013.01.768","type":"journal-article","created":{"date-parts":[[2013,4,18]],"date-time":"2013-04-18T11:05:35Z","timestamp":1366283135000},"page":"590-603","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":36,"title":["A Randomized, Double-Blind, Placebo-Controlled Trial to Assess the Efficacy and Safety of Gabapentin Enacarbil in Subjects With Neuropathic Pain Associated With Postherpetic Neuralgia (PXN110748)"],"prefix":"10.1016","volume":"14","author":[{"given":"Lixin","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Rainka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roy","family":"Freeman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. Norman","family":"Harden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher F.","family":"Bell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ole","family":"Graff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen","family":"Harding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Setrina","family":"Hunter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Kavanagh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bart","family":"Laurijssens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caryl","family":"Schwartzbach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha","family":"Warren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carrie","family":"McClung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpain.2013.01.768_bib1","first-page":"613","article-title":"Clinical pharmacokinetics of gabapentin","volume":"31","author":"Bockbrader","year":"1995","journal-title":"Drugs Today"},{"key":"10.1016\/j.jpain.2013.01.768_bib2","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1177\/0091270008322909","article-title":"Clinical pharmacokinetics of XP13512, a novel transported prodrug of gabapentin","volume":"48","author":"Cundy","year":"2008","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.jpain.2013.01.768_bib3","first-page":"1","article-title":"The incidence and prevalence of neuropathic pain","author":"Cunnington","year":"2004","journal-title":"GlaxoSmithkline Rx Communications"},{"key":"10.1016\/j.jpain.2013.01.768_bib4","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1212\/01.WNL.0000055433.55136.55","article-title":"Pregabalin for the treatment of postherpetic neuralgia: A\u00a0randomized, placebo-controlled trial","volume":"60","author":"Dworkin","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.jpain.2013.01.768_bib5","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1086\/510206","article-title":"Recommendations for the management of herpes zoster","volume":"44","author":"Dworkin","year":"2007","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jpain.2013.01.768_bib6","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.pain.2004.09.012","article-title":"Core outcome measures for chronic pain clinical trials: IMMPACT recommendations","volume":"113","author":"Dworkin","year":"2005","journal-title":"Pain"},{"key":"10.1016\/j.jpain.2013.01.768_bib7","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.pain.2009.08.019","article-title":"Interpreting the clinical importance of group differences in chronic pain clinical trials: IMMPACT recommendations","volume":"146","author":"Dworkin","year":"2009","journal-title":"Pain"},{"key":"10.1016\/j.jpain.2013.01.768_bib8","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.pain.2009.02.007","article-title":"Development and initial validation of an expanded and revised version of the Short-form McGill Pain Questionnaire (SF-MPQ-2)","volume":"144","author":"Dworkin","year":"2009","journal-title":"Pain"},{"key":"10.1016\/j.jpain.2013.01.768_bib9","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S0304-3959(01)00349-9","article-title":"Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale","volume":"94","author":"Farrar","year":"2001","journal-title":"Pain"},{"key":"10.1016\/j.jpain.2013.01.768_bib10","unstructured":"Horizant (gabapentin enacarbil) Prescribing Information Research Triangle Park (NC) and Santa Clara (CA): GlaxoSmithKline and XenoPort, Inc. Available at http:\/\/us.gsk.com\/products\/assets\/us_horizant.pdf. Accessed 1 June 2012"},{"key":"10.1016\/j.jpain.2013.01.768_bib11","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1097\/AJP.0b013e3181934276","article-title":"Efficacy and tolerability of gastric-retentive gabapentin for the treatment of postherpetic neuralgia: Results of a double-blind, randomized, placebo-controlled clinical trial","volume":"25","author":"Irving","year":"2009","journal-title":"Clin J Pain"},{"key":"10.1016\/j.jpain.2013.01.768_bib12","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1097\/AJP.0b013e318192bf87","article-title":"Assessment of pain quality in a clinical trial of gabapentin extended release for postherpetic neuralgia","volume":"25","author":"Jensen","year":"2009","journal-title":"Clin J Pain"},{"key":"10.1016\/j.jpain.2013.01.768_bib13","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1056\/NEJM199607043350107","article-title":"Postherpetic neuralgia\u2013pathogenesis, treatment and prevention","volume":"335","author":"Kost","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jpain.2013.01.768_bib14","article-title":"Population pharmacokinetics and pharmacodynamics of gabapentin after administration of gabapentin enacarbil","author":"Lal","year":"2012","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.jpain.2013.01.768_bib15","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1023\/B:PHAM.0000003371.32474.ee","article-title":"The use of clinical trial simulation to support dose selection: Application to development of a new treatment for chronic neuropathic pain","volume":"20","author":"Lockwood","year":"2003","journal-title":"Pharm Res"},{"key":"10.1016\/j.jpain.2013.01.768_bib16","unstructured":"Neurontin (gabapentin) Prescribing Information. New York (NY): Pfizer, Inc. Available at http:\/\/labeling.pfizer.com\/ShowLabeling.aspx?id=630. Accessed 1 Mar 2012"},{"key":"10.1016\/j.jpain.2013.01.768_bib17","doi-asserted-by":"crossref","first-page":"S22","DOI":"10.1016\/j.amjmed.2009.04.007","article-title":"Treatment of Neuropathic Pain: An overview of Recent Guidelines","volume":"122","author":"O'Connor","year":"2009","journal-title":"Am J Med"},{"key":"10.1016\/j.jpain.2013.01.768_bib18","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/S0304-3959(01)00407-9","article-title":"Gabapentin in postherpetic neuralgia: A randomized double blind, placebo controlled study","volume":"94","author":"Rice","year":"2001","journal-title":"Pain"},{"key":"10.1016\/j.jpain.2013.01.768_bib19","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1001\/jama.280.21.1837","article-title":"Gabapentin for the treatment of postherpetic neuralgia. A randomized controlled trial","volume":"280","author":"Rowbotham","year":"1998","journal-title":"JAMA"},{"key":"10.1016\/j.jpain.2013.01.768_bib20","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.pain.2004.01.001","article-title":"Pregabalin reduces pain and improves sleep and mood disturbances in patients with post-herpetic neuralgia: Results of a randomised, placebo-controlled clinical trial","volume":"109","author":"Sabatowski","year":"2004","journal-title":"Pain"},{"key":"10.1016\/j.jpain.2013.01.768_bib21","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1185\/030079906X80404","article-title":"Efficacy and tolerability of twicedaily pregabalin for treating pain and related sleep interference in postherpetic neuralgia: A 13-week, randomized trial","volume":"22","author":"van Seventer","year":"2006","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.jpain.2013.01.768_bib22","doi-asserted-by":"crossref","first-page":"765","DOI":"10.2165\/11539520-000000000-00000","article-title":"Gabapentin extended-release tablets for the treatment of patients with postherpetic neuralgia: A randomized, double-blind, placebo-controlled, multicentre study","volume":"30","author":"Wallace","year":"2010","journal-title":"Clin Drug Investig"},{"key":"10.1016\/j.jpain.2013.01.768_bib23","series-title":"Multiple Comparisons and Multiple Tests using the SAS\u00ae System","author":"Westfall","year":"1999"},{"key":"10.1016\/j.jpain.2013.01.768_bib24","first-page":"938","article-title":"Post-herpetic-neuralgia: A review of advances in treatment and prevention","volume":"5","author":"Young","year":"2006","journal-title":"J Drugs Dermatol"}],"container-title":["The Journal of Pain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526590013008067?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526590013008067?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T19:53:58Z","timestamp":1761508438000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1526590013008067"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,6]]},"references-count":24,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2013,6]]}},"alternative-id":["S1526590013008067"],"URL":"https:\/\/doi.org\/10.1016\/j.jpain.2013.01.768","relation":{},"ISSN":["1526-5900"],"issn-type":[{"value":"1526-5900","type":"print"}],"subject":[],"published":{"date-parts":[[2013,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Randomized, Double-Blind, Placebo-Controlled Trial to Assess the Efficacy and Safety of Gabapentin Enacarbil in Subjects With Neuropathic Pain Associated With Postherpetic Neuralgia (PXN110748)","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pain","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpain.2013.01.768","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}